Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine

Behavioural Brain Research

Volumn 243, Issue 1, 2013, Pages 205-212

  Gruden, Marina A ^a   Davidova, Tatiana V ^c   Yanamandra, Kiran ^b   Kucheryanu, Valery G ^c   Morozova Roche, Ludmilla A ^b   Sherstnev, Vladimir V ^a   Sewell, Robert D E ^d  

^a P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

^b UMEÅ UNIVERSITY   (Sweden)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Synuclein oligomers; Autoantibodies; Dopamine; Fibrils; Locomotor activity; Rigidity; Rodent

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN FIBRIL; ALPHA SYNUCLEIN FIBRIL AUTOANTIBODY; ALPHA SYNUCLEIN MONOMER; ALPHA SYNUCLEIN MONOMER AUTOANTIBODY; ALPHA SYNUCLEIN OLIGOMER; ALPHA SYNUCLEIN OLIGOMER AUTOANTIBODY; AUTOANTIBODY; DOPAMINE; DOPAMINE AUTOANTIBODY; THIOFLAVINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ATOMIC FORCE MICROSCOPY; AUTOIMMUNITY; BEHAVIOR DISORDER; BEHAVIORAL SCIENCE; BINDING ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; MUSCLE RIGIDITY; NEUROTOXICITY; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN UNFOLDING;

ADMINISTRATION, INTRANASAL; ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MUSCLE RIGIDITY; PARKINSON DISEASE, SECONDARY; VACCINATION;

EID: 84873497620     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.011     Document Type: Article

References (76)

1. Luheshi L.M., Dobson C.M. Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Letters 2009, 583:2581-3256.
2. Hervás R., Oroz J., Galera-Prat A., Goñi O., Valbuena A., Vera A.M., et al. Common features at the start of the neurodegeneration cascade. PLoS Biology 2012, 10(5):e1001335.
3. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302(5646):819-822.
4. Uversky V.N. Alpha-synuclein misfolding and neurodegenerative diseases. Current Protein and Peptide Science 2008, 9:507-540.
5. Park N.H. Parkinson disease. Journal of the American Academy of Physician Assistants 2012, 25:73-74.
6. Rivers R.C., Kumita J.R., Tartaglia G.G., Dedmon M.M., Pawar A., Vendruscolo M., et al. Molecular determinants of the aggregation behavior of alpha- and beta-synuclein. Protein Science 2008, 17:887-898.
7. Uversky V.N., Dunker A.K. Understanding protein non-folding. Biochimica et Biophysica Acta 2010, 1804:1231-1264.
8. De Genst E., Dobson C.M. Nanobodies as structural probes of protein misfolding and fibril formation. Methods in Molecular Biology 2012, 911:533-558.
9. Fernagut P.O., Hutson C.B., Fleming S.M., Tetreaut N.A., Salcedo J., Masliah E., et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007, 61:991-1001.
10. Binukumar B.K., Bal A., Kandimalla R.J., Gill K.D. Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α-synuclein aggregation, oxidative damage and behavioral changes. Molecular Brain 2010, 3:35.
11. Prediger R.D., Aguiar A.S., Moreira E.L., Matheus F.C., Castro A.A., Walz R., et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Current Pharmaceutical Design 2011, 17:489-507.
12. Bazzu G., Calia G., Puggioni G., Spissu Y., Rocchitta G., Debetto P., et al. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. CNS & Neurological Disorders Drug Targets 2010, 9:482-490.
13. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease 2006, 22:404-420.
14. Blandini F., Armentero M.T. Animal models of Parkinson's disease. FEBS Journal 2012, 279(7):1156-1166. doi: 10.1111/j. 1742-4658.2012.08491.x.
15. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. Journal of Neural Transmission 2001, 108:1263-1282.
16. Schintu N., Frau L., Ibba M., Garau A., Carboni E., Carta A.R. Progressive dopaminergic degeneration in the chronic MPTP mouse model of Parkinson's disease. Neurotoxicity Research 2009, 16:127-139.
17. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Annals of Neurology 2008, 64(Suppl. 2):S16-S29.
18. Chiueh C., Markey S.P., Burns R.S., Johannessen J.N., Pert A., Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. European Journal of Pharmacology 1984, 100:189-194.
19. Kalaria R.N., Mitchell M.J., Harik S.I. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proceedings of the National Academy of Sciences 1987, 84:3521-3525.
20. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: systemic administration. Journal of Pharmacology and Experimental Therapeutics 1994, 270:1000-1007.
21. Harik S.I., Schmidley J.W., Iacofano L.A., Blue P., Arora P.K., Sayre L.M. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. Journal of Pharmacology and Experimental Therapeutics 1987, 241:669-676.
22. Da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behavioural Brain Research 2001, 124:9-18.
23. Da Cunha C., Angelucci M.E.M., Canteras N.S., Wonnacott S., Takahasha R.N. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's Disease memory disabilities. Cellular and Molecular Neurobiology 2002, 22:227-237.
24. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. Journal of Neuroscience Methods 2005, 148:78-87.
25. Prediger R.D., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Experimental Neurology 2006, 202:391-403.
26. Prediger R.D., Rial D., Medeiros R., Figueiredo C.P., Doty R.L., Takahashi R.N. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease. Annals of the New York Academy of Sciences 2009, 1170:629-636.
27. Moreira E.L.G., Rial D., Aguiar A.S., Figueiredo C.P., Siqueira J.M., DalBó S., et al. Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. Journal of Neural Transmission 2010, 117:1337-1351.
28. Castro A.A., Ghisoni K., Latini A., Quevedo J., Tasca C.I., Prediger R.D.S. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behavioural Brain Research 2012, 229:208-215.
29. Stoica G., Lungu G., Bjorklund N.L., Taglialatela G., Zhang X., Chiu V., et al. Potential role of α-synuclein in neurodegeneration: studies in a rat animal model. Journal of Neurochemistry 2012, 122(4):812-822.
30. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Research. Molecular Brain Research 2005, 134:57-66.
31. Fuller R.W., Hemrick-Luecke S.K. Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice. Toxicology Letters 1990, 54:253-262.
32. Decressac M., Mattsson B., Bjorkland A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Experimental Neurology 2012, 235(1):306-315.
33. Decressac M., Mattsson B., Lundblad M., Weikop P., Bjorkland A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated over-expression of alpha-synuclein in midbrain dopamine neurons. Neurobiology of Disease 2012, 45:939-953.
34. Lindgren H.S., Lelos M.J., Dunnett S.B. Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model. Experimental Neurology 2012, 237:36-42.
35. Rojo A.I., Montero C., Salazar M., Close R.M., Fernández-Ruiz J., Sánchez-González M.A., et al. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. European Journal of Neuroscience 2006, 24:1874-1884.
36. Prediger R.D.S., Aguiar A.S., Matheus F.C., Walz R., Antoury L., Raisman-Vozari R., et al. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotoxicity Research 2012, 21:90-116.
37. Orr C.F., Rowe D.B., Mizuno Y., Mori H., Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-2674.
38. Roodveldt C., Christodoulou J., Dobson C.M. Immunological features of alpha-synuclein in Parkinson's disease. Journal of Cellular and Molecular Medicine 2008, 12:1820-1829.
39. Gruden M.A., Sewell R.D.E., Yanamandra K., Davidova T.V., Kucheryanu V.G., Bocharov E.V., et al. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. Journal of Neuroimmunology 2011, 233:221-227.
40. Gruden M.A., Yanamandra K., Kucheryanu V.G., Bocharova O.R., Sherstnev V.V., Morozova-Roche L.A., et al. Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation. Neuroimmunomodulation 2012, 19(6):334-342.
41. Yanamandra K., Gruden M.A., Casaite V., Meskys R., Forsgren L., Morozova-Roche L.A. α-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 2011, 6(4):e18513.
42. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007, 2:141-151.
43. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behavioural Brain Research 2001, 125:109-125.
44. Tillerson J.L., Caudle W.M., Reverón M.E., Miller G.W. Detection of behavioural impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Experimental Neurology 2002, 178:80-90.
45. Ugrumov M.V., Khaindrava V.G., Kozina E.A., Kucheryanu V.G., Bocharov E.V., Kryzhanovsky G.N. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience 2011, 181:175-188.
46. Kryzhanovsky G.N., Kucheryanu V.G., Krupina N.A., Pozdnyakov O.M., Kladkevich E.B., Nikushkin E.V., et al. Effects of fibroblast growth factors on MPTP-induced parkinsonian syndrome in mice. Pathophysiology 1997, 4:59-67.
47. Ben-Sreti M.M., Sewell R.D.E., Upton N. Some observations on the effects of two enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine. Archives Internationales de Pharmacodynamie et de Therapie 1982, 256:219-227.
48. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Medicine 1998, 4:1318-1320.
49. Hoyer W., Antony T., Cherny D., Heim G., Jovin T.M., Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. Journal of Molecular Biology 2002, 322:383-393.
50. Morozova-Roche L.A., Zurdo J., Spencer A., Noppe W., Receveur V., Archer D.B., et al. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. Journal of Structural Biology 2000, 130:339-351.
51. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Science 1993, 2:404-410.
52. Malisauskas M., Zamotin V., Jass J., Noppe W., Dobson C.M., Morozova-Roche L.A. Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration. Journal of Molecular Biology 2003, 330:879-890.
53. Gruden M.A., Davidova T.B., Malisauskas M., Sewell R.D.E., Voskresenskaya N.I., Wilhelm K., et al. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta (25-35) oligomers, S100b and neurotransmitters. Journal of Neuroimmunology 2007, 186:181-192.
54. Wan O.W., Chung K.K. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS ONE 2012, 7(6):e38545.
55. Paleologou K.E., Kragh C.L., Mann D.M., Salem S.A., Al-Shami, Allsop D., et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1101.
56. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
57. Bertoncini C.W., Jung Y.S., Fernandez C.O., Hoyer W., Griesinger C., Jovin T.M., et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proceedings of the National Academy of Sciences 2005, 102:1430-1435.
58. Foltynie T., Michell A.W., Barker R.A. Parkinson's disease: What is it? What causes it? And how can it be cured. Protein Misfolding in Neurodegenerative Diseases. Mechanisms and therapeutic strategies 2008, 381-414. CRC Press, New York. H.J. Smith, C. Simonds, R.D.E. Sewell (Eds.).
59. Celej M.S., Sarroukh R., Goormaghtigh E., Fidelio G.D., Ruysschaert J.M., Raussens V. Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. Biochemical Journal 2012, 443(3):719-726.
60. Hansen C., Beyond Li J.Y. α-synuclein transfer: pathology propagation in Parkinson's disease. Trends in Molecular Medicine 2012, 18(5):248-255.
61. Colla E., Jensen P.H., Pletnikova O., Troncoso J.C., Glabe C., Lee M.K. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. Journal of Neuroscience 2012, 32(10):3301-3305.
62. Tsigelny I.F., Sharikov Y., Wrasidlo W., Gonzalez T., Desplats P.A., Crews L., et al. Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS Journal 2012, 279:1000-1013.
63. Stöckl M., Claessens M.M., Subramaniam V. Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers. Molecular Biosystems 2012, 8(1):338-345.
64. Arif I.A., Khan H.A. Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress. Toxicology and Industrial Health 2010, 26:121-128.
65. Barnett E.M., Perlman S. The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM. Virology 1993, 194:185-191.
66. Barber P.C., Raisman G. An autoradiographic investigation of the projection of the vomeronasal organ to the accessory olfactory bulb in the mouse. Brain Research 1974, 81:21-30.
67. Ma M., Grosmaitre X., Iwema C.L., Baker H., Greer C.A., Shepherd G.M. Olfactory signal transduction in the mouse septal organ. Journal of Neuroscience 2003, 23:317-324.
68. Roppolo D., Ribaud V., Jungo V.P., Lüscher C., Rodriguez I. Projection of the Grüneberg ganglion to the mouse olfactory bulb. European Journal of Neuroscience 2006, 23:2887-2894.
69. Doty R.L. The olfactory vector hypothesis of neurodegenerative disease: is it viable?. Annals of Neurology 2008, 63:7-15.
70. Luk K.C., Song C., O'Brien P., Stieber A., Branch J.R., Brunden K.R., et al. α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proceedings of the National Academy of Sciences 2009, 106:20051-20056.
71. Matheus F.C., Aguiar A.S., Castro A.A., Villarinho J.G., Ferreira J., Figueiredo C.P., et al. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behavioural Brain Research 2012, 235(2):263-272.
72. Cremades N., Cohen S.I., Deas E., Abramov A.Y., Chen A.Y., Orte A., et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012, 149:1048-1059.
73. Näsström T., Gonçalves S., Sahlin C., Nordström E., Screpanti Sundquist V., Lannfelt L. Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS ONE 2011, 6(10):e27230.
74. Emadi S., Liu R., Yuan B., Schulz P., McAllister C., Lyubchenko Y., et al. Inhibiting asggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004, 43:2871-2878.
75. Emadi S., Barkhordarian H., Wang M.S., Schulz P., Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein induced toxicity. Journal of Molecular Biology 2007, 368:1132-1144.
76. Perez R.G., Hastings T.G. Could a loss of alpha-synuclein function put dopaminergic neurons at risk. Journal of Neurochemistry 2004, 89:1318-1324.